SynapCell is an innovative CRO helping drug developers find the most effective #drugs to cure brain diseases using #EEG biomarkers in clinically-relevant models
We will be attending the AD/PD 2025 Conference on #Alzheimer’s & #Parkinson’s diseases! As a CRO partner in #preclinicalEEG for #CNSDrugDiscovery, we’re eager to connect with researchers, biotech innovators, pharma experts to advance strategies for neurodegenerative diseases.
March is Essential Tremor Month !
#Essentialtremor (ET) is one of the most common movement disorders, yet the impact of the disease on the patients’ quality of life remains underestimated and treatment options are limited.
#Neuroscience#EEG
🎶 Let’s talk Auditory Evoked Potentials ! (#AERP)
40Hz-Auditory Steady State Response (#ASSR) is a robust and translational auditory evoked potential that describes the resonance properties of stimulus-driven neural circuits.
#EEG#neuroscience
Even if your drug effectively treats a CNS disorder, it may also influence sleep architecture—positively or negatively. Identifying these effects early is crucial, and preclinical studies can help forecast them!
Want to see how this works? 👉 Check out our poster
Billions are invested in drug discovery every year, yet the clinical failure rate remains dauntingly high. We understand the complexities and challenges our sponsors face in developing effective treatments for central nervous system (#CNS) disorders.
#DrugDiscovery#CNSdisorders
📅 Meet SynapCell at the upcoming #Neuroscience & #Epilepsy events in 2025! 💡If you’re working on #preclinical#CNS#drugdiscovery and development, and looking for data-driven insights to guide your study with confidence, contact us or let’s connect at one of these events.
⚡#Epilepsy is a complex spectrum of disorders requiring a tailored #DrugDiscovery approach. Choosing the right model for the right seizure type is key. SynapCell provides gold-standard #preclinical & #translational models to predict drug efficacy with advanced #EEG biomarkers.
🟪 Today, on #WorldEpilepsyDay, we take a stand - not just to raise awareness, but to drive progress. Let’s use this day to amplify voices, advance research, and create a future where #Epilepsy is no longer a barrier to life.
Need 𝗽𝗿𝗲𝗰𝗶𝘀𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝗯𝗲𝘁𝘁𝗲𝗿 𝗽𝗿𝗼𝗳𝗶𝗹𝗲 𝘆𝗼𝘂𝗿 𝗰𝗼𝗺𝗽𝗼𝘂𝗻𝗱? Let’s discuss how pharmaco-sleep-EEG can refine and potentiate your next step in #CNS#drugdiscovery at the #preclinical step. #EEG
👉https://t.co/zOJW09LJ3y
📌Join us at the 8th Annual Neuroscience Innovation Forum, January 21-23, 2025: Discover how SynapCell can help accelerate drug development and provide decision-making data with #translational and predictive #EEG#biomarkers and reference models of #CNS disorders.
#neuroscience
As we wrap up another year, we would like to thank all our customers & partners. Your support fuels our mission to drive excellence in the future of neuroscience & drug discovery. Many thanks for your confidence & support in making this possible. Merry Christmas & Happy New Year!
AES 2024: @Supernus_Pharma presented their work on the effects of SPN-817 on Hippocampal Paroxysmal Discharge occurrence in the Mesial Temporal Lobe #Epilepsy model, with great results.
🤩They trusted us with the #preclinical#EEG work on our #MTLE model. TY!
#drugdiscovery
AES 2024: SynapCell's Amygdala Kindling poster is out ! 🤝
This poster highlights the pharmacology of the model by showing 5 typical Antiseizure Medications (ASMs) and their associated readouts for each of them. 💊
#EEG#drugdiscovery#epilepsy
📢📢 Proud to present a new poster from a collaboration between @Supernus_Pharma & SynapCell on the "Effects of SPN-817 on Hippocampal Paroxysmal Discharge Occurrence in the Mesial Temporal Lobe Epilepsy Model" at the American Epilepsy Society Annual Meeting 2024.
📢📢 Discover our new poster at the American #Epilepsy Society Annual Meeting 2024: “Pharmacological Assessment of Anti-Seizure Medications in the Amygdala-Kindling Model” - Board 1.397 / Dec. 7, 2024, 12:00 - 6:00 PM
- Booth #2141 -
#CRO#DrugDiscovery#CNS#EEG#preclinical
📢 SynapCell will unveil a new #Epilepsy model - the Amygdala Kindling model - along with its translational #EEG biomarker at the American Epilepsy Society Annual Meeting 2024 in Los Angeles, from December 6–10, 2024.
👉 Stop by our booth #2141 to learn more!
📢📢 International Pharmaco-EEG Society Conference (IPEG) 2024: Meet SynapCell’s scientists in Izmir, Turkey, from November 21 to 24, 2024. Let’s discuss Science and explore how #preclinical#EEG can accelerate #CNS drug discovery.
Stop by SynapCell's poster at #sfn2024 this morning (board X32) : Assessing sleep architecture and pharmacodynamics : an EEG-based platform for drug testing - PSTR311.0
#SfN24#eeg#neuroscience